We have identified 14 patients with diverse primary immunodeficiencies who have developed progressive neurodegeneration of unknown etiology. All patients had received immunoglobulin replacement therapy for a mean duration of 6.5 years (range of 0.5-13.5 years) at the time of first neurological symptoms. Diagnostic tests of blood and cerebrospinal fluid analyses included chemistry, cultures, PCR for viral genomes, and cytology. In addition, neuroimaging and electrophysiologic studies were performed. Brain tissue histology (n ‫؍‬ 5) revealed nonspecific encephalitis with microglial infiltration and neuronal loss. Twelve patients died 6 months to 15 years (median 4.3 years) after onset of neurologic findings. No evidence of any infectious disease that could have explained our patients' progressive encephalopathy was found either during their lifetimes or postmortem. These patients may have had an unusual manifestation of primary immunodeficiency diseases, an autoimmune reaction against neuronal tissue, a yet undefined infectious agent, or a complication of IVIG therapy. To help determine the etiology of this rare complication, an international surveillance system for primary immunodeficiency patients who develop progressive neurodegeneration of unknown cause is recommended.
We have identified 14 patients with diverse primary immunodeficiencies who have developed progressive neurodegeneration of unknown etiology. All patients had received immunoglobulin replacement therapy for a mean duration of 6.5 years (range of 0.5-13.5 years) at the time of first neurological symptoms. Diagnostic tests of blood and cerebrospinal fluid analyses included chemistry, cultures, PCR for viral genomes, and cytology. In addition, neuroimaging and electrophysiologic studies were performed. Brain tissue histology (n ‫؍‬ 5) revealed nonspecific encephalitis with microglial infiltration and neuronal loss. Twelve patients died 6 months to 15 years (median 4.3 years) after onset of neurologic findings. No evidence of any infectious disease that could have explained our patients' progressive encephalopathy was found either during their lifetimes or postmortem. These patients may have had an unusual manifestation of primary immunodeficiency diseases, an autoimmune reaction against neuronal tissue, a yet undefined infectious agent, or a complication of IVIG therapy. To help determine the etiology of this rare complication, an international surveillance system for primary immunodeficiency patients who develop progressive neurodegeneration of unknown cause is recommended. INTRODUCTION In 1995, the World Health Organization (WHO) Scientific Group reported 7000 known cases of primary immunodeficiency diseases (PID) worldwide (1), a number that vastly underestimates the true incidence. The majority of these patients have defective B cell function (2) , resulting in significant antibody deficiency and the need for lifelong immunoglobulin replacement therapy. In the United States alone, 17-18 tons of intravenous immunoglobulin (IVIG) are used per year (3), 30% of which is given to patients with PID.
To produce a single lot of IVIG, plasma units from up to 60,000 donors are pooled (4), and a single lot can serve up to tens of thousands of doses (5) . Despite the large donor pool, the only infectious agent ever known to have been transmitted by IVIG infusion is the hepatitis C virus (HCV), a complication that occurred prior to the availability of serologic methods and polymerase chain reaction (PCR) to identify and eliminate potentially HCV-contaminated units (6) . Although the transmission of Creutzfeldt-Jacob disease (CJD) by blood products has never been confirmed, this possibility remains a concern, and the subsequent diagnosis of CJD in a plasma donor was considered a potential safety hazard, causing the recall of several batches of IVIG (7) .
Aseptic meningitis, headaches, and thromboembolic events, leading to stroke, have been reported as neurologic side effects associated with IVIG therapy (8) . However, none of these conditions have been reported as being progressive in nature, and IVIG has emerged as an effective therapy for various neurologic diseases, including demyelinating neuropathies, neuromuscular diseases, myopathies, and certain childhood epilepsies (9 -11).
Certain immunodeficient patients are highly susceptible to vaccine-associated paralytic poliomyelitis. Furthermore, agammaglobulinemic patients are prone to have chronic enteroviral infections due to the lack of neutralizing antibodies (12) . Chronic enteroviral central nervous system (CNS) disease, manifesting with headaches, seizures, hearing loss, lethargy, ataxia, paresthesia, diminished intellectual acuity, loss of milestones, and behavioral alterations, seems to precede subsequent dissemination, presenting as dermatomyositis-like syndrome, including myositis-fasciitis, edema and erythematous rashes, hepatitis, myocarditis, and arthritis. With the introduction of IVIG in 1982, which allowed a higher IgG trough level than that observed during IM immunoglobulin therapy, a marked reduction of enteroviral encephalopathies was noticed.
In this multicenter study we collected and retrospectively analyzed reports of 14 PID patients who had developed progressive neurodegenerative disease while on IVIG therapy without positive detection of any causative infectious agent. We provide demographic information, clinical presentation, and diagnostic studies. The intent of this analysis is to alert immunologists and neurologists of the existence of this phenomenon and to initiate an early surveillance system for PID patients on IVIG.
MATERIALS AND METHODS

Patients
Fourteen PID patients, all Caucasians, ages 4 to 62 years (median 16 years), qualified for inclusion in the study (Table 1) . Four patients had X-linked agammaglobulinemia (XLA), five had X-linked hyper-IgM syndrome (XHIM), one had severe combined immunodeficiency (SCID), one combined immunodeficiency (CID), and three patients had common variable immunodeficiency (CVID). Seven cases each were identified in Europe and in the U.S.A. Two of fourteen patients were female (patients 10 and 11); an expected predominance of males was due to a high frequency of X-linked inheritance in the study population.
Two XLA patients had a positive family history, and mutations within the Bruton tyrosine kinase (Btk) gene were identified in three patients. All four XLA patients had low numbers of B lymphocytes and low serum immunoglobulins. Patients with XHIM had low serum IgG and IgA and elevated IgM levels (three cases), a positive family history (three cases), and mutations of the CD40 ligand (identified in four of the five patients). The SCID patient had hypogammaglobulinemia, lymphopenia (T Ϫ , B Ϫ , NK ϩ ), severely reduced in vitro lymphocyte proliferation to mitogens, a positive family history (brother with SCID), and a mother with random X-chromosome inactivation in lymphocytes, suggestive of autosomal recessive inheritance. The CID patient had residual T cell function. A molecular diagnosis was available in neither the SCID nor the CID case. The diagnosis of CVID (two of the three CVID patients were female) was based on low serum immunoglobulin levels, abnormal antibody responses, depressed isohemagglutinins, and in some cases impaired cell-mediated immunity, but normal numbers of circulating B lymphocytes.
IVIG Exposure
IVIG infusions were started between 2 months and 56 years of age (median 1.8 years). The following IVIG brands were used: Sandoglobulin, Venoglobin-S, Polygam S/D, Gammagard S/D, Gamimune N, Endobulin, Octagam, Intraglobin, Polyglobin, Gammonativ, and Immunglobulin Berna. Most patients were exposed to two or more products, depending on the availability of the blood product, and most received the recommended dose of 400 -500 mg/kg every 3 to 4 weeks.
Testing for Infectious Diseases
To explain the neurologic abnormalities, all patients underwent extensive testing for infectious agents known to cause meningoencephalitis and neurodegenerative disease. Specimens available from most patients included serum, blood, and cerebrospinal fluid (CSF). Brain tissue was obtained by biopsy (one case) or autopsy (four cases). Because multiple centers and laboratories were involved and the patients were frequently studied over many years, the specimens were often analyzed by different techniques. Most patients had laboratory evaluations for bacterial, viral, and fungal infections using cultures, histologic techniques, and more recently PCR. Testing was performed for enteroviruses (EV), including ECHO, coxsackie and polio strains, Epstein-Barr virus (EBV), cytomegalovirus (CMV), parvovirus, herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), polyoma viruses, human herpes virus (HHV) 6, 7, and 8, measles, human T cell leukemia/lymphoma virus (HTLV), human immunodeficiency virus (HIV), rotavirus, respiratory syncytial virus (RSV), hepatitis virus A, B, C, and G, mycoplasma, chlamydia, borrelia, toxoplasma, toxocara, leishmania, and Giardia lamblia. Not every patient underwent all testing (Table 2) . Two patients had blood tested for CJD by immunoblotting, one each in laboratories at the NIH and in Madrid, Spain, and all five brain tissue specimens were histologically evaluated for spongiform encephalitis.
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Testing for Neurologic Deficits
The neurologic status of each patient was closely monitored and followed throughout the period of CNS disease. All patients underwent neuroimaging using computerized tomogram (CT) scanning and/or magnetic resonance imaging (MRI) and CSF analysis. In addition, 13 patients had at least one electroencephalogram (EEG). In single cases, positron emission tomography (PET) scans, single proton emission computerized tomograms (SPECT), electromyelograms (EMG), and cerebral angiography were performed. Five patients developed vision problems and underwent an extensive ophthalmologic evaluation.
RESULTS
Clinical Course
All 14 PID patients, while on immunoglobulin replacement therapy, developed progressive neurodegenerative disease (Table 1 ). The youngest patient was 16 months old, and the oldest was 56 years at onset of neurologic symptoms (median age 11 years). At the time the diagnosis of neuropathologic disease was established, immunoglobulin replacement therapy had been instituted for from 6 months to 13.5 years (median 6.5 years).
Neurologic symptoms were observed in all patients. Eleven developed dementia, including loss of language skills and memory, and cognitive impairment. Language deficit affected predominantly expression rather than reception and comprehension. Seven patients suffered from ataxia and incoordination. Five patients Five patients experienced an ophthalmopathy with optic nerve atrophy and a retinitis pigmentosa-like picture, leading to transient blurred vision and turning into amblyopia in two patients. Autopsy of one of the patients with ophthalmopathy revealed partial demyelinization and gliosis of the optic nerve.
Other symptoms included progressive loss of cognitive activities (n ϭ 3), attention deficit (n ϭ 3), incontinence (n ϭ 1), tetraparesis (n ϭ 1), transverse myelitis (n ϭ 1), mood swings (n ϭ 1), and aggression and paranoia (n ϭ 1).
Patient 7 was treated with intrathecal IVIG, which did not change his rapidly progressive neurologic deterioration.
Patient 3 was empirically treated with a 3-week course of Pleconaril (3-[3,5- 
, an investigational antipicornaviral agent, preventing replication by inhibiting viral uncoating as well as attachment to the host cell (13) . This treatment, approved for compassionate use only, had no effect on our patient's progressive deterioration.
To date, progressive neurodegenerative disease has resulted in the death of 12 patients, between the ages of 4 and 62 years (median age at death 13.5 years). Death occurred 0.5 to 15 years (median 4.3 years) after the first neurological symptoms began. The two living patients, ages 24 and 25 years, suffer from progressive dementia.
Search for Infectious Agents
Because of the retrospective nature of the study, the extent of the search for an infectious agent varied from patient to patient (Table 2) .
Hepatitis C infection, diagnosed with patient 11, is known to cause hepatic encephalopathy. However, since the neurologic symptoms had preceded this patient's hepatitis C infection, this is not a likely explanation.
Patient 6 had disseminated histoplasmosis prior to the CNS disease, but there was no evidence of fungal disease in CSF cultures and at autopsy.
Postmortem, patient 7 was found to have a positive PCR for CMV in the brain tissue. However, the histology did show neither inclusion bodies nor evidence of an inflammatory process that would have been expected in a patient with XHIM. Furthermore, blood, urine, bronchoalveolar lavage, and CSF, tested by PCR, and cultures for CMV had been repeatedly negative.
Particular attention was given to enteroviral infections, which prior to the IVIG era often caused progressive encephalitis leading to dementia, especially in patients with XLA (12) . All patients tested negative for enterovirus, including ECHO, coxsackie, and poliovirus, by culture or PCR. Histological examination of brain tissue from five patients did not show the microscopic pattern of spongiform encephalopathy, eliminating CJD.
Neurodiagnostic Tests
CT and/or MRI revealed brain atrophy with prominent sulci and enlarged ventricles (Fig. 1) in all 14 cases. EEGs showed abnormalities in 11 of 13 patients, consisting of slow waves (n ϭ 4), epileptiform activity (n ϭ 4), or both (n ϭ 3). CSF was abnormal in 6 of 14 patients, as demonstrated by elevated protein, observed in 3 cases, and pleocytosis, all mononuclear cells, seen in 5 cases; 2 patients had both findings. PET showed global hypometabolism and SPECT showed multifocal hypoperfusion in one case. An EMG was normal in a patient with ataxia and spasticity of his lower extremities. A brain stem auditory evoked potential and visual evoked potential were abnormal in a patient with ophthalmopathy and motor symptoms. Histologic findings of brain tissue, obtained from 1 patient by biopsy and from 4 patients by autopsy, included reactive astrocytic gliosis, microglial infiltration, patchy demyelinization and neuronal loss, involving basal ganglia, brain stem, cortex, and, in 1 patient, distinctive loss of Purkinje cells of the cerebellar cortex.
DISCUSSION
This retrospective study reports 14 patients with PID who developed progressive neurodegenerative disease of unknown etiology. Because of the antibody deficiency, all patients were on immunoglobulin replacement therapy for variable time periods prior to the onset of the neurologic symptoms. These cases were followed and investigated independently at diverse medical centers in Europe and the United States and were collected retrospectively by personal communication.
The first description of a similar clinical phenotype involving PID patients was published in 1996 (14) , reporting the association of hypogammaglobulinemia and progressive encephalomyelitis. In four of these cases, also included in this report, no causative infectious agent could be identified despite thorough testing 22 for possible transmission from plasma products. The search for enteroviruses, known to be a serious problem for XLA patients (12), was repeatedly negative by cultures or PCR. Also, despite progressive CNS disease, none of our patients had experienced any symptoms of disseminated enteroviral infection, which could be expected at that stage. The studies for infectious agents as well as other diagnostic tests were carried out at local laboratories by common standard techniques. Since 12 of 14 of our patients have expired, fresh specimens for a systematic analysis are no longer available from these patients.
Brain tissues obtained from 5 patients were negative for spongiform encephalopathy, ruling out PRION disease. Histologic changes included nonspecific degenerative changes with variable degrees of cellular responses, which may be due in part to the lymphocyte abnormalities associated with the underlying immune defect. The histological findings correlate well with the general brain atrophy as confirmed by CT/MRI.
The etiology of this progressive dementing neuropathy is unclear. Infectious agents could not be identified, neither by cultures nor by PCR, and serologic testing is not conclusive in immunodeficient patients. The retrospective nature of this study did not allow for standardized testing in a single laboratory. If infectious agents are responsible for this neurodegenerative disease-so far without any evidence-they could involve a yet unidentified microorganism, i.e., a virus, possibly transmitted by IVIG. The remote possibility that toxic chemicals or antineural tissue antibodies, potentially present in IVIG, could cause these irreversible and therapy-resistant neurologic changes has to be considered. Most patients were exposed to more than one brand of IVIG, depending on the availability of the product. Considering the large numbers of patients that receive IVIG infusions on a regular basis and the small number of known affected cases, and the fact that our patients had received IVIG from many different sources, IVIG as an etiology for the described encephalopathy is less likely. The chance that this may be an unusual presentation of primary immunodeficiency diseases is also remote because of the multiple genetic defects represented in these patients. So far, we were unable to identify an autoimmune response to neuronal tissue as a cause for the severe dementia: 
PID PATIENTS WITH PROGRESSIVE NEURODEGENERATION
Only five patients underwent serologic testing to rule out autoimmune disease, and none of the obtained brain tissue biopsies has been evaluated for immune complex deposits.
Although the number of affected patients is small considering the entire population of PID patients, the seriousness of the clinical presentation, the unresponsiveness to medications, the irreversibility, and the progression to dementia and death are of concern. For these reasons, immunologists and neurologists caring for such patients will have to develop new strategies to solve this serious complication of PID. We propose a simple protocol designed to follow such patients, including sequential testing of at least three specimens for enteroviruses by PCR and cultures as well as an empiric treatment with Pleconaril. To facilitate active monitoring of PID patients on IVIG therapy with neurological findings, we intend to establish an international database and registry. A questionnaire for clinicians has been developed and is available at the URL http://www.pid-neurodegeneration.org.
